About us Contacts Drug interactions: 390 212
Drug search by name

Nuplazid and Zykadia

Determining the interaction of Nuplazid and Zykadia and the possibility of their joint administration.

Check result:
Nuplazid <> Zykadia
Relevance: 01.12.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme. According to the product labeling, pimavanserin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.5- and 3-fold, respectively, when given with the potent CYP450 3A4 inhibitor ketoconazole. High plasma levels of pimavanserin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death. MANAGEMENT: Pimavanserin dosage should be reduced by one-half (from 34 mg to 17 mg once daily) when used with potent CYP450 3A4 inhibitors. References "Product Information. Nuplazid (pimavanserin)." Accelis Pharma, East Windsor, NJ.

Professional:

ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme. According to the product labeling, pimavanserin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 1.5- and 3-fold, respectively, when given with the potent CYP450 3A4 inhibitor ketoconazole. High plasma levels of pimavanserin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.

MANAGEMENT: Pimavanserin dosage should be reduced by one-half (from 34 mg to 17 mg once daily) when used with potent CYP450 3A4 inhibitors.

References
  • "Product Information. Nuplazid (pimavanserin)." Accelis Pharma, East Windsor, NJ.
Nuplazid

Generic Name: pimavanserin

Brand name: Nuplazid

Synonyms: n.a.

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction